Clinical Trials

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05006716 2026-04-22

CaDAnCe-101

Phase 1/2 Recruiting

614 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06073821 2026-04-22

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06637501 2026-04-22

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

94 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Phase 2 Recruiting

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06846671 2026-04-22

CaDAnCe-302

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06970743 2026-04-22

CaDAnCe-303

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06973187 2026-04-22

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07099443 2026-04-22

REBELLE

Phase NA Recruiting

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07277231 2026-04-22

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02553447 2026-04-21

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

Phase NA Completed

197 enrolled 15 charts

Lymphoma, Non-Hodgkin, Vitamin D Deficiency, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00039676 2026-04-20

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Active not recruiting

1,836 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00720785 2026-04-20

Natural Killer Cells and Bortezomib to Treat Cancer

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03328273 2026-04-20

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1 Active not recruiting

12 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03932331 2026-04-20

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05020678 2026-04-20

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

150 enrolled

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05254743 2026-04-20

BRUIN-CLL-314

662 enrolled

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05724121 2026-04-20

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

135 enrolled

Arrhythmias, Cardiac, Atrial Fibrillation, Leukemia, Lymphocytic, Chronic, B-Cell, Death, Sudden, Cardiac, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06859008 2026-04-20

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07194980 2026-04-20

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

20 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03960840 2026-04-17

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

217 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05294731 2026-04-17

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1/2 Recruiting

146 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06761586 2026-04-17

VIJAY-1

Phase 1 Terminated

9 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07162181 2026-04-17

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

13 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07218341 2026-04-17

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 4 Recruiting

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07288515 2026-04-17

ALICIA(BY)

50 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00466531 2026-04-16

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

50 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02131584 2026-04-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

10 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06548152 2026-04-16

AQUALIS

120 enrolled

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled 15 charts

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT04329728 2026-04-15

OPAL

Phase 1/2 Recruiting

144 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06943872 2026-04-15

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Phase 1 Recruiting

24 enrolled

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00923507 2026-04-14

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

1,000 enrolled

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02514083 2026-04-14

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

29 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04169737 2026-04-14

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Recruiting

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05131022 2026-04-14

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1 Recruiting

572 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07221500 2026-04-14

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Phase 2 Recruiting

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01589302 2026-04-13

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT01804686 2026-04-13

CAN3001

700 enrolled

Phase 3 Active not recruiting

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01890486 2026-04-13

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen